Tags

Type your tag names separated by a space and hit enter

Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression.
J Clin Endocrinol Metab. 2013 May; 98(5):E934-42.JC

Abstract

CONTEXT

The relevance of the BRAF V600E mutation in papillary thyroid carcinoma (PTC) as a negative prognostic factor is a subject of intense debate. This mutation has been associated with several clinicopathological features, but the lack of consistency among data does not support its usefulness as marker of tumor aggressiveness and poorer outcome. Due to the genetic heterogeneity of the tumor, both the occurrence and the allele percentage of the BRAF mutation should be considered to unravel this controversy.

OBJECTIVE

We aimed to evaluate the impact of the BRAF V600E mutation occurrence and the allele percentage on the metastatic process in PTCs.

STUDY DESIGN

The presence and allele percentage of the BRAF mutation were determined by pyrosequencing in 132 cases of well-differentiated PTCs with (n = 37) or without lymph node metastases (LNMs) (n = 95) and in 40 LNMs matched with 35 PTCs.

RESULTS

No significant differences were observed in either the occurrence or the allele percentage of V600E mutation between the 2 groups of PTCs with or without LNMs. The LNMs were heterogeneous for the V600E mutation as the primary lesions.

CONCLUSIONS

In this study, the occurrence and percentage of the BRAF V600E mutated allele was not preferentially associated with the development of metastases and the average mutated allele percentage decreased as the tumor progresses from the primary site to the lymph node metastatic sites. These observations support the need to reevaluate the role of the BRAF V600E mutation as a negative prognostic marker in PTCs.

Authors+Show Affiliations

Laboratory of Molecular Biology, Department of Oncology, Arcispedale S. Maria Nuova-Istituto di Ricovero e Cura a Carattere Scientifico, Viale Risorgimento 80, 42123 Reggio Emilia, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23533235

Citation

Gandolfi, Greta, et al. "Allele Percentage of the BRAF V600E Mutation in Papillary Thyroid Carcinomas and Corresponding Lymph Node Metastases: No Evidence for a Role in Tumor Progression." The Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 5, 2013, pp. E934-42.
Gandolfi G, Sancisi V, Torricelli F, et al. Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression. J Clin Endocrinol Metab. 2013;98(5):E934-42.
Gandolfi, G., Sancisi, V., Torricelli, F., Ragazzi, M., Frasoldati, A., Piana, S., & Ciarrocchi, A. (2013). Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression. The Journal of Clinical Endocrinology and Metabolism, 98(5), E934-42. https://doi.org/10.1210/jc.2012-3930
Gandolfi G, et al. Allele Percentage of the BRAF V600E Mutation in Papillary Thyroid Carcinomas and Corresponding Lymph Node Metastases: No Evidence for a Role in Tumor Progression. J Clin Endocrinol Metab. 2013;98(5):E934-42. PubMed PMID: 23533235.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression. AU - Gandolfi,Greta, AU - Sancisi,Valentina, AU - Torricelli,Federica, AU - Ragazzi,Moira, AU - Frasoldati,Andrea, AU - Piana,Simonetta, AU - Ciarrocchi,Alessia, Y1 - 2013/03/26/ PY - 2013/3/28/entrez PY - 2013/3/28/pubmed PY - 2013/7/6/medline SP - E934 EP - 42 JF - The Journal of clinical endocrinology and metabolism JO - J. Clin. Endocrinol. Metab. VL - 98 IS - 5 N2 - CONTEXT: The relevance of the BRAF V600E mutation in papillary thyroid carcinoma (PTC) as a negative prognostic factor is a subject of intense debate. This mutation has been associated with several clinicopathological features, but the lack of consistency among data does not support its usefulness as marker of tumor aggressiveness and poorer outcome. Due to the genetic heterogeneity of the tumor, both the occurrence and the allele percentage of the BRAF mutation should be considered to unravel this controversy. OBJECTIVE: We aimed to evaluate the impact of the BRAF V600E mutation occurrence and the allele percentage on the metastatic process in PTCs. STUDY DESIGN: The presence and allele percentage of the BRAF mutation were determined by pyrosequencing in 132 cases of well-differentiated PTCs with (n = 37) or without lymph node metastases (LNMs) (n = 95) and in 40 LNMs matched with 35 PTCs. RESULTS: No significant differences were observed in either the occurrence or the allele percentage of V600E mutation between the 2 groups of PTCs with or without LNMs. The LNMs were heterogeneous for the V600E mutation as the primary lesions. CONCLUSIONS: In this study, the occurrence and percentage of the BRAF V600E mutated allele was not preferentially associated with the development of metastases and the average mutated allele percentage decreased as the tumor progresses from the primary site to the lymph node metastatic sites. These observations support the need to reevaluate the role of the BRAF V600E mutation as a negative prognostic marker in PTCs. SN - 1945-7197 UR - https://www.unboundmedicine.com/medline/citation/23533235/Allele_percentage_of_the_BRAF_V600E_mutation_in_papillary_thyroid_carcinomas_and_corresponding_lymph_node_metastases:_no_evidence_for_a_role_in_tumor_progression_ L2 - https://academic.oup.com/jcem/article-lookup/doi/10.1210/jc.2012-3930 DB - PRIME DP - Unbound Medicine ER -